Flagship Ventures announced CEO of its newest startup, called Codiak BioSciences, to be Doug Williams who oversaw the scientific efforts at Biogen (Nasdaq: BIIB) during that company’s rise to become one of the world’s foremost biotech firms as well as the Massachusetts’ most valuable company (Forbes, Former Biogen R&D Chief Emerges at $80M Startup Pursuing Cancer, Alzheimer’s, NOV 17, 2015, View Source [SID:1234508271]). Schedule your 30 min Free 1stOncology Demo! Codiak Biosciences is developing exosomes, natural vesicles that mediate inter-cellular communication, as both a powerful therapeutic modality and an advanced diagnostic system. Codiak is building a world-class team and has generated and acquired foundational intellectual property that will allow it to capitalize on the unique potential of exosome biology.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The initial focus of Codiak will be pancreatic cancer. The company will seek to build on research Kalluri’s team published in Nature in June (View Source), in which Kalluri and his team had identified a proteoglycan called Glypican-1, which was present on the surface of exosomes.